BTAI
BioXcel Therapeutics Inc.
$2.78
-$0.21(-7.02%)
50
Overall
--
Value
50
Tech
--
Quality
Market Cap
$43.52M
Volume
1.49M
52W Range
$1.17 - $13.28
Target Price
$8.25
Order:
Income Statement
| Metric | Trend | Chart | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Total Revenue | -- | -- | -- | -- | $375.0K | $1.4M | $2.3M | ||
| Total Revenue | -- | -- | -- | -- | $375.0K | $1.4M | $2.3M | ||
| COST OF GOODS SOLD | |||||||||
| Cost of Revenue | -- | -- | -- | -- | $20.0K | $1.3M | $2.1M | ||
| GROSS PROFIT | |||||||||
| Gross Profit | -- | -- | -- | -- | $355.0K | $120.0K | $123.0K | ||
| OPERATING EXPENSES | |||||||||
| Operating Expenses | $-20.0M | $-33.6M | $82.3M | $106.9M | $160.0M | $167.7M | $64.9M | ||
| Research & Development | $14.6M | $25.8M | $58.0M | $52.7M | $91.2M | $84.3M | $30.4M | ||
| Research Expense | $14.6M | $25.8M | $58.0M | $52.7M | $91.2M | $84.3M | $30.4M | ||
| Selling, General & Administrative | $5.4M | $7.8M | $24.3M | $54.2M | $68.8M | $83.4M | $34.5M | ||
| General & Administrative Expenses | $5.4M | $7.8M | $24.3M | $54.2M | $68.8M | $83.4M | $34.5M | ||
| Salaries & Wages | $-3.1M | $-3.1M | -- | -- | -- | $18.6M | $6.2M | ||
| Depreciation & Amortization | $-17.0K | $-155.0K | $188.0K | $297.0K | $327.0K | $318.0K | $309.0K | ||
| Depreciation & Amortization | $-17.0K | $-155.0K | $188.0K | $297.0K | $327.0K | $318.0K | $309.0K | ||
| Amortization | -- | -- | -- | -- | $860.0K | $1.4M | $467.0K | ||
| Other Operating Expenses | -- | $-155.0K | $345.0K | $365.0K | $410.0K | $173.2M | $69.5M | ||
| OPERATING INCOME | |||||||||
| Operating income | $-20.0M | $-33.6M | $-82.3M | $-106.9M | $-159.6M | $-171.8M | $-67.2M | ||
| EBITDA | $-19.3M | $-32.8M | $-82.0M | $-106.6M | $-157.2M | $-179.4M | $-44.2M | ||
| NON-OPERATING ITEMS | |||||||||
| Interest Expense (Non-Operating) | -- | $20.0K | $27.0K | $40.0K | $8.2M | $11.9M | $14.7M | ||
| Interest Income Operating | -- | $653.0K | $155.0K | -- | -- | -- | -- | ||
| Intinc | $692.0K | $633.0K | $155.0K | $44.0K | $2.5M | $5.6M | $2.6M | ||
| Net Non-Operating Interest Income/Expense | $692.0K | $-20.0K | $128.0K | $4.0K | $-5.7M | $5.6M | $2.6M | ||
| Gain on Sale of Securities | -- | -- | -- | -- | -- | $438.0K | $20.2M | ||
| Other Income/Expense | -- | -- | -- | -- | $-427.0K | $-394.0K | $-20.2M | ||
| Other Special Charges | -- | -- | -- | -- | $-427.0K | $394.0K | $20.2M | ||
| SPECIAL ITEMS | |||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | $4.2M | $2.4M | ||
| Special Income Charges | -- | -- | -- | -- | $-807.0K | $-4.2M | $-2.4M | ||
| PRE-TAX INCOME | |||||||||
| EBIT | $-19.3M | $-32.9M | $-82.1M | $-106.9M | $-157.5M | $-181.4M | $-45.3M | ||
| Pre-Tax Income | $-19.3M | $-33.0M | $-82.2M | $-106.9M | $-165.8M | $-165.7M | $-59.6M | ||
| INCOME TAX | |||||||||
| Tax Provision | -- | -- | -- | -- | -- | $-14.3M | $-343.0K | ||
| NET INCOME | |||||||||
| Net Income | $-19.3M | $-33.0M | $-82.2M | $-106.9M | $-165.8M | $-179.1M | $-59.6M | ||
| Net Income (Continuing Operations) | $-19.3M | $-33.0M | $-82.2M | $-106.9M | $-165.8M | $-179.1M | $-59.6M | ||
| Net Income (Discontinued Operations) | $-19.3M | $-33.0M | $-82.2M | $-106.9M | $-165.8M | $-179.1M | $-59.6M | ||
| Net Income (Common Stockholders) | $-19.3M | $-33.0M | $-82.2M | $-106.9M | $-165.8M | $-179.1M | $-59.6M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-42.4M | ||
| TOTALS | |||||||||
| Total Expenses | $-20.0M | $-33.6M | $82.3M | $106.9M | $160.0M | $169.0M | $67.1M | ||
| SHARE & EPS DATA | |||||||||
| Average Shares Outstanding | $910.7K | $1.0M | $1.4M | $1.6M | $1.8M | $1.8M | $2.5M | ||
| Average Shares Outstanding (Diluted) | $912.4K | $1.0M | -- | $1.6M | $1.8M | $1.8M | $2.5M | ||
| Shares Outstanding | $979.0K | $1.3M | $1.5M | $1.7M | $1.8M | $1.9M | $5.5M | ||
| Basic EPS | -- | -- | $-60.64 | $-64.8 | $-94.72 | $-98.4 | $-23.51 | ||
| Basic EPS (Continuing Operations) | -- | -- | $-60.64 | $-64.8 | $-94.72 | $-98.4 | $-23.51 | ||
| Diluted EPS | $-21.12 | $-32.32 | $-60.64 | $-64.8 | $-94.72 | $-98.4 | $-23.51 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-64.8 | $-94.72 | $-98.4 | $-23.51 | ||
| OTHER METRICS | |||||||||
| Other Gand A | $5.4M | $7.8M | $24.3M | $54.2M | $68.8M | $83.4M | $34.5M | ||
| Rent And Landing Fees | $5.4M | $7.8M | -- | -- | -- | -- | -- | ||
| Othspecchg | -- | -- | -- | -- | $807.0K | $1.9M | -- | ||
| Restruct | -- | -- | -- | -- | -- | $4.2M | $2.4M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BTAI | $2.78 | -7.0% | 1.49M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get BioXcel Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW